Titan Pharmaceuticals is a pharmaceutical company developing therapeutics utilizing its drug delivery platform, ProNeura, for the treatment of select chronic diseases. Probuphine is a product based on its ProNeura technology approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder (OUD). Co. is conducting non-clinical studies with a nalmefene implant for the potential treatment of OUD under a grant from the National Institutes of Health. Co. is collaborating with the Walter Reed Army Institute of Research and South West Research Institute in the early non-clinical evaluation of the ProNeura platform in malaria prophylaxis. The TTNP stock yearly return is shown above.
The yearly return on the TTNP stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2013 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TTNP annual return calculation with any dividends reinvested as applicable (on ex-dates).
|